Approved
- Episodios
- 6
- Se publica
- sin periodicidad fija
- Último episodio
- 18 Sep 2026
Sobre el podcast
Life sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.
Episodios 6
Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise
Rate & Subscribe!!!The wild story of how a Cold War bioweapon became Botox — and how Allergan turned a sleepy ophthalmology drug into an enduring aesthetic franchise.Every part of this story looks nothing like …
Notas del episodio
Rate & Subscribe!!!
The wild story of how a Cold War bioweapon became Botox — and how Allergan turned a sleepy ophthalmology drug into an enduring aesthetic franchise.
Every part of this story looks nothing like your normal blockbuster drug. Botox started its development storyas a Cold War bioweapon so lethal the CIA was thinking of using it on Castro. Decades later, an eye surgeon in San Francisco mortgaged his house and managed to bootstrap his way to a BLA– no venture capital needed! After a contentious sale to a sleepy eye-drop company called Allergan, it turned Botox into one of the most durable, recurring-revenue franchises in the history of medicine.
That cash cow provoked all sorts of financial battles– a hostile takeover attempt involving Bill Ackman, a tax-inversion scheme with Pfizer that united Bernie Sanders and Donald Trump in opposition, and a far-fetched plan to rent a Native American tribe's sovereign immunity to protect a different drug's patents.
In this episode, we trace Botox from a 19th-century German sausage poisoning, through a Cold War weapons lab, an eye surgeon's garage-scale manufacturing operation, and into Allergan's decades-long reign — covering the science of why the drug still has no biosimilar, the "aesthetics stack" that turned it into a subscription business for faces, and the corporate finance drama (Valeant, Actavis, Pfizer and AbbVie) that followed. Along the way: exclusive interviews with Allergan's 95-year-old founding CEO, the scientist who helped manufacture the original drug substance in an academic lab, and the dermatologist who tried to repurpose Botox to treat depression.In this episode:
- How a Clostridium botulinum strain donated for free by a Harvard professor became the physical basis of a multi-billion-dollar drug
- Why the FDA's insistence on unique nonproprietary names (onabotulinumtoxinA vs. abobotulinumtoxinA) created an accidental, unbreakable competitive moat
- How Allergan built the "surround the ophthalmologist" sales playbook — and later applied the same tactics to the aesthetic space.
- The 2014 Valeant/Ackman hostile takeover attempt, and how Allergan fought back
- How nearly every foundational piece of IP in the Botox story was given away for free by the academics who created it
- Is there a new aesthetic bundle to build around incretin-based weight loss products?
Featuring quotes from: Gavin Herbert Jr. (Allergan founder and former chairman/CEO), Eric Johnson, PhD (Ed Schantz's research partner, University of Wisconsin), Eric Finzi, MD PHD (dermatologist and Botox-for-depression researcher), Brent Saunders (former CEO, Allergan/Actavis), and Amy Ingle, APRN (owner, Sweet Spot Medispo).Bibliography
Selected sources. Compiled September 2026.
Books
Helveston, Eugene M. Death to Beauty: The Transformative History of Botox. Bloomington: Indiana University Press, 2023. iupress.org
Berkowitz, Dana. Botox Nation: Changing the Face of America. New York: New York University Press, 2017. nyupress.org
Finzi, Eric. The Face of Emotion: How Botox Affects Our Mood and Relationships. New York: Palgrave Macmillan, 2013. publishersweekly.com
Essays and criticism
Shaywitz, David. “Botox: A Luminous Example of Field Discovery.” Timmerman Report, February 9, 2024. timmermanreport.com
Shaywitz, David. “‘Death to Beauty’ Review: The Birth of Botox.” The Wall Street Journal, February 12, 2024. aei.org
Business school case studies
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. “The Allergan Board Under Fire (A).” Harvard Business School Case 316-010. Boston: Harvard Business School, 2016 (rev. January 7, 2019). hbsp.harvard.edu
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. “The Allergan Board Under Fire (B).” Harvard Business School Case 316-029. Boston: Harvard Business School, 2016 (rev. January 7, 2019). hbsp.harvard.edu
Peterson, Randall S., and Lisa Duke. “David Pyott: The Battle for Allergan (A).” London Business School Case CS-16-001. London: London Business School, September 2018. Distributed by Harvard Business Publishing, no. LBS305. hbsp.harvard.edu
Foroughi, Jaclyn, and Rebecca Lester. “The Pfizer-Allergan Tax Inversion.” Stanford Graduate School of Business Case A-230. Stanford, CA: Stanford GSB, 2017. Distributed by Harvard Business Publishing. hbsp.harvard.edu
Primary scientific literature
van Ermengem, Emile. “A New Anaerobic Bacillus and Its Relation to Botulism.” Reviews of Infectious Diseases 1, no. 4 (1979): 701–19. Translation of “Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus,” Zeitschrift für Hygiene und Infektionskrankheiten 26 (1897): 1–56. PMID 399378
Erbguth, Frank J., and Markus Naumann. “Historical Aspects of Botulinum Toxin: Justinus Kerner (1786–1862) and the ‘Sausage Poison.’” Neurology 53, no. 8 (1999): 1850–53. PMID 10563638
Schantz, Edward J., and Eric A. Johnson. “Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine.” Microbiological Reviews 56, no. 1 (1992): 80–99. PMID 1579114
Scott, Alan B. “Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery.” Ophthalmology 87, no. 10 (1980): 1044–49. PMID 7243198
Carruthers, Jean D., and J. Alastair Carruthers. “Treatment of Glabellar Frown Lines with C. botulinum-A Exotoxin.” Journal of Dermatologic Surgery and Oncology 18, no. 1 (1992): 17–21. PMID 1740562
Dodick, David W., et al. “OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results from the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program.” Headache 50, no. 6 (2010): 921–36. PMID 20487038
Finzi, Eric, and Norman E. Rosenthal. “Treatment of Depression with OnabotulinumtoxinA: A Randomized, Double-Blind, Placebo Controlled Trial.” Journal of Psychiatric Research 52 (2014): 1–6. PMID 24345483
Brin, Mitchell F., et al. “OnabotulinumtoxinA for the Treatment of Major Depressive Disorder: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial in Adult Females.” International Clinical Psychopharmacology 35, no. 1 (2020): 19–28. PMID 31609787
The depression program after Allergan
Healis Therapeutics. “Healis Therapeutics Acquires Ownership of Key Botulin...
What is Approved?
Approved tells the definitive stories behind the world's most interesting biotech ventures. Most people learn about the industry in a fragmented, ad hoc way-- an industry article here, a clinical trial readout …
Notas del episodio
Approved tells the definitive stories behind the world's most interesting biotech ventures.
Most people learn about the industry in a fragmented, ad hoc way-- an industry article here, a clinical trial readout there, some science twitter. In contrast, The Approved podcast tells comprehensive, definitive stories of how drugs are discovered, developed and sold. Whether we're tracking a single blockbuster drug's remarkable rise, or following a single startup’s decade-long path to approval, every episode we put out is an unvarnished look at how the biotech industry works. We break down what worked, what failed, and distill insights that you can apply to your own life science business. Every episode is accessible and entertaining, but ultimately designed for the life science professional.
Hosted by Matthew Pech, PhD (cancer biologist and drug hunter) and Alex Kesin (biotech writer), every episode draws on hundreds of hours of research -- including Nature papers, corporate decks, SEC filings, and legal records. All that is supplemented with original interviews with the actual scientists, operators, and clinicians who brought the drugs to life.
Season 1 Highlights- Keytruda: Featuring conversations with Roy Baynes and Greg Carven.
- Blueprint Medicines: Featuring Christoph Lengauer and Alexis Borisy.
- Botox: Featuring Gavin Herbert Jr. and Brent Saunders.
Season 1 is wrapping up soon, with our upcoming episode on a drug worth 285 million times its weight in gold (guesses are welcome). Research for Season 2 is already underway...
Subscribe on Apple Podcasts and Spotify, or visit approved.fm.Blueprint Medicines: Chasing Gleevec to a $9B Allergy Drug
Blueprint Medicines was built to find the next Gleevec-style cancer drug. It ended up pivoting to allergic disease instead, and selling to Sanofi for $9B. This is the platform, the pivot, and who got …
Notas del episodio
Blueprint Medicines was built to find the next Gleevec-style cancer drug. It ended up pivoting to allergic disease instead, and selling to Sanofi for $9B. This is the platform, the pivot, and who got paid.
Blueprint Medicines set out to be the natural sequel to Gleevec: a company founded by two of the scientists behind that landmark cancer drug, built to order by Third Rock Ventures' "venture creation" model, with a proprietary kinase-inhibitor library designed to drug the 517 other broken molecular switches Gleevec couldn't touch.A decade later, Sanofi paid roughly $9 billion for the company... just not for a cancer drug. Blueprint's blockbuster asset, avapritinib (AYVAKIT), found its real market almost by accident: indolent systemic mastocytosis, a debilitating, often-undiagnosed mast-cell disease that took patients years to get diagnosed and had no approved treatment.
In this episode, we trace two threads at once: the science of designing truly selective kinase inhibitors, and the venture capital philosophy -- company creation, not just company funding -- that built Blueprint from a whiteboard sketch into a platform biotech. We cover the near-death Series B, the accidental discovery that opened up mastocytosis, the GAVRETO partnership that fell apart against a faster competitor, the Sanofi negotiation (CVRs and all), and the wide gap between what the venture firm and hired executives made versus what the founding scientists -- like Gleevec's co-inventor Nick Lydon -- walked away with. We end covering the efforts of Blueprint diaspora to create a new model of seed investing: Curie Bio.Featuring interviews with:
- Alexis Borisy: Former Blueprint CEO/Chairman; founding chairman, Curie.Bio
- Christoph Lengauer: Founding CSO, Blueprint Medicines; Chief Drug Hunter, Curie.Bio
- Erica Evans: Former VP Biology, Blueprint Medicines; SVP, Curie.Bio
- Tim Guzi: Former Head of Medicinal Chemistry, Blueprint Medicines
- Dr. Charles Sawyers, M.D. — Academic co-founder, Blueprint Medicines
- Dr. Mariana Castells, M.D., Ph.D — Director, Mastocytosis Center, Brigham and Women's Hospital
CREDITS
Co-hosted by Alex Kesin and Matthew Pech
Written, edited, and produced by Alex Kesin
Music: “Food” by nerowski
* Special thanks to the team at NFX for the use of their recording studio.
Sources
1. Books and case studies- Vasella, Daniel, with Robert Slater. Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History. HarperBusiness, New York, 2003. ISBN 9780060010300 · OCLC 50859163.
- Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 29, 2020.
- Levin, Mark. "Mastering the Value Chain: An Interview with Mark Levin of Millennium Pharmaceuticals." Harvard Business Review, June 2001.
2. SEC filingsBlueprint Medicines (CIK 1597264)
- Form S-1, March 23, 2015.
- Stockholders Agreement (Ex. 4.5), November 7, 2014.
- Investors' Rights Agreement (Ex. 4.4), November 7, 2014.
- Schedule 14D-9, June 17, 2025.
- Schedule 14D-9 Amendment No. 1, July 10, 2025.
- Schedule 14D-9 Amendment No. 3, July 18, 2025.
- Form 8-K — Roche immunokinase collaboration press release, March 18, 2016.
- Form 8-K — VOYAGER Phase 3 topline, April 28, 2020.
- Form 8-K — Roche pralsetinib collaboration press release, July 14, 2020.
- Roche Collaboration Agreement (Ex. 10.1 to Q2 2020 10-Q).
- Form 8-K — Royalty Pharma + Sixth Street financing, June 30, 2022.
- Form 10-K, FY2022.
- Form 8-K — Roche termination of Gavreto collaboration, February 23, 2023.
- Form 8-K — EGFR program discontinuation, January 8, 2024.
- Form 8-K — Gavreto handoff to Rigel, February 22, 2024.
- Form 8-K — BLU-222 deprioritization, January 13, 2025.
- CORRESP — response to SEC accounting comments, 2021.
- DEF 14A, 2018.
- DEF 14A, 2019.
- DEF 14A, 2021.
- DEF 14A, June 18, 2025.
SanofiCapítulos
Cargando capítulos…
Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time
Keytruda is Merck's $31 billion a year PD-1 inhibitor and the best-selling cancer drug of all time. In Episode 3 of Approved, Alex Kesin and Matthew Pech trace the development of pembrolizumab , featuring …
Notas del episodio
Keytruda is Merck's $31 billion a year PD-1 inhibitor and the best-selling cancer drug of all time. In Episode 3 of Approved, Alex Kesin and Matthew Pech trace the development of pembrolizumab , featuring interviews the scientists who drove the program forward : co-inventors Gregory Carven and Michel Streuli, and former Merck oncology CMO Roy Baynes.
Topics include preclinical PD1 / CTLA-4 checkpoint biology that brought industry attention to the target (Jim Allison's CTLA-4 work and Tasuku Honjo's PD-1 discovery); how pembro started as a failed rheumatoid arthritis antibody program at a Dutch subsidiary of a paint company; the two mega-mergers that nearly killed the program; the biomarker enrichment trial design behind KEYNOTE-024 that let Merck break BMS's lead in lung cancer; the 41-patient Johns Hopkins MSI-H trial behind the first tissue-agnostic FDA approval, and the Jimmy Carter melanoma case that brought pembrolizumab to the public conscious. The episode closes on what comes next for Merck: the 2028 patent cliff, the Keytruda QLEX subcutaneous launch, and efforts to find the next blockbuster checkpoint inhibitor, including Summit/Akeso's PD-1 / VEGF bispecific ivonescimab.
CHAPTERS
00:00:00 — Introduction: The Best-Selling Cancer Drug of All Time
00:02:15 — Part One — A Century of Failed Cancer Immunotherapy
00:04:17 — T Cells, CD28, and the Two-Signal Model of Immune Activation
00:06:25 — Jim Allison's CTLA-4 Discovery and the Path to Yervoy
00:12:03 — Tasuku Honjo Discovers PD-1: A Better Brake on T Cells
00:14:26 — Lieping Chen and the PD-L1 Tumor Evasion Hypothesis
00:16:26 — Part Two — Organon: The Dutch Paint-Company Subsidiary Behind Keytruda
00:19:48 — How Michel Streuli Caught the Solid-Phase Screening Artifact
00:22:09 — The Accidental Antagonist: From Rheumatoid Arthritis Drug to Cancer Drug
00:26:34 — Sponsor: Grant Detmer (JLL) on Biotech Real Estate Strategy
00:30:01 — Russian Nesting-Doll M&A: Schering-Plough Acquires Organon (2007)
00:31:43 — The $41 Billion Merck–Schering-Plough Mega-Merger of 2009
00:34:58 — Corporate Guerrilla Warfare: Four Scrappy Stunts That Saved Pembrolizumab
00:39:32 — BioNovion's Spite-Company Bid to Buy Pembro Back
00:42:10 — BMS at ASCO 2010: The Data Print That Revived Merck's PD-1 Program
00:45:55 — Part Three — Roger Perlmutter Joins a Bleeding Merck (April 2013)
00:50:48 — "Let Me Manage the Tigers": Ken Frazier Backs the All-In Bet on Pembrolizumab
00:55:22 — Breakthrough Therapy Designation and Eric Rubin's Adaptive Trial Design
00:58:25 — Keytruda's 2014 FDA Approval Erases BMS's Four-Year Lead
01:00:24 — The Lung Cancer Battlefield and the PD-L1 Biomarker Bet
01:02:19 — BMS vs. Merck: All-Comers vs. Biomarker-Enriched Trial Strategy
01:08:18 — KEYNOTE-024 vs. CheckMate-026: The Trial That Decided the Category
01:12:03 — Luis Diaz, MSI-H, and the Failed BMS Trial That Made Keytruda Tissue-Agnostic
01:17:18 — KEYNOTE-189: Perlmutter's Bet on Combining Keytruda with Chemotherapy
01:19:21 — Merck's Clinical Development Playbook: Basket Trials, Backwards March, External Collabs
01:25:29 — Part Four — The IO Graveyard: TIGIT, CD47, IDO1, LAG-3 and Tens of Billions Incinerated
01:30:23 — Why PD-1 Was the Only Checkpoint That Worked (Lieping Chen Revisited)
01:33:32 — Part Five — Inside the Best-Selling Drug of All Time
01:37:03 — "Build a Wall, High and Wide": Merck’s Commercial Strategy for Keytruda
01:43:44 — Part Six — The Patent Cliff and Loss of Exclusivity in Pharma
01:45:35 — Keytruda QLEX (Subcutaneous) and the Lifecycle Management Playbook
01:50:23 — PD-1/VEGF Bispecifics: Ivonescimab, Summit Therapeutics, and the Next Threat
01:55:31 — The Scorecard: Patient, Academic, and Financial Impact
02:01:19 — Who Actually Profited: Merck vs. Organon vs. the Scientists Who Built the Drug
02:05:54 — Epilogue: The Jimmy Carter DrugSources
Last updated: May 2026
Essential reading- Shaywitz, David. "The Startling History Behind Merck's New Cancer Blockbuster." Forbes, Jul 26, 2017. The definitive Organon-era origin story.
- Loftus, Peter. "Why Merck Is Betting Big on One Cancer Drug." WSJ, Apr 15, 2018. Source for Perlmutter's "whatever other projects you're working on, you can stop now."
- Lowe, Derek. "The Keytruda Story." In the Pipeline.
- Graeber, Charles. The Breakthrough. Twelve, 2018.
Primary interviewsGreg Carven, Michel Streuli, Roy Baynes — Approved podcast interviews (2026). Quotes attributed to these speakers come from these conversations unless otherwise noted.
Foundational science- Stutman. "Tumor development in athymic-nude mice." Science (1974). The flawed experiment that killed tumor immunology for two decades.
- Shankaran et al. "IFNγ and lymphocytes prevent primary tumour development." Nature (2001). Schreiber's cancer immunoediting paper.
- Leach, Krummel & Allison. "Antitumor immunity by CTLA-4 blockade." Science (1996). Allison's '100-to-zero' experiment.
- Ishida, Agata, Shibahara & Honjo. "Induced expression of PD-1." EMBO J (1992). Honjo discovers PD-1.
- Dong, Strome et al. "B7-H1 promotes T-cell apoptosis." Nat Med (2002). Lieping Chen's PD-L1 immune-evasion paper.
Pivotal trials- Topalian et al. "Anti-PD-1 in cancer." NEJM (2012). BMS nivolumab Phase 1 — woke Merck up.
- Hamid et al.
Episode #2: Geron
Listen on SpotifyListen on Apple PodcastsListen on YouTubeTABLE OF CONTENTS(00:00:00) - Introduction (00:01:19) - Hayflick Limit (00:08:30) - Michael West & Founding of Geron (00:15:16) - Early Science & IP …
Notas del episodio
Listen on Spotify
Listen on Apple Podcasts
Listen on YouTube
TABLE OF CONTENTS
(00:00:00) - Introduction
(00:01:19) - Hayflick Limit
(00:08:30) - Michael West & Founding of Geron
(00:15:16) - Early Science & IP Strategy
(00:27:25) - Cloning the Telomerase Gene
(00:29:30) - Embryonic Stem Cells & Political Context
(00:44:21) - Okarma, West’s Departure & Corporate Turmoil
(01:05:08) - Spinal Cord Injury Trial
(01:30:45) - Pivot to Blood Cancer
(01:43:08) - Clinical & Commercial Drama
(02:01:45) - Legacy & Lessons
CREDITS
Co-hosted by Alex Kesin and Matthew Pech
Written, edited, and produced by Alex Kesin
Music: “Food” by nerowski
* Special thanks to the team at NFX for the use of their recording studio.
SOURCES
Last updated: March 2026
I. BOOKS
II. KEY SCIENTIFIC PUBLICATIONS
Feng, J. et al. “The RNA component of human telomerase.” Science 269, no. 5228 (1995): 1236–1241.
III. REGULATORY & CLINICAL
ICER. “Evidence Report: Treatment for Anemia in Myelodysplastic Syndrome.” August 2024.
ICER. Press Release on Imetelstat Evidence Assessment.
ClinicalTrials.gov. GRNOPC1 Phase I Trial. NCT01217008.
Myelodysplastic Syndrome Epidemiology. PMC4553145.
MDS Risk and AML Progression. Blood (2023).
IV. CORPORATE FILINGS & PRESENTATIONS
Episode #1: Amylin Pharmaceuticals
Listen on SpotifyListen on Apple PodcastsListen on YouTubeTABLE OF CONTENTS(00:00:00) - Introduction(00:04:40) - $50 of Dried Lizard Venom(00:29:17) - Fax of Death(00:43:04) - Sleeping Beauty Awakens(00:52:07) …
Notas del episodio
Listen on Spotify
Listen on Apple Podcasts
Listen on YouTube
TABLE OF CONTENTS
(00:00:00) - Introduction
(00:04:40) - $50 of Dried Lizard Venom
(00:29:17) - Fax of Death
(00:43:04) - Sleeping Beauty Awakens
(00:52:07) - Carl Icahn Sends a Letter
(01:09:19) - Endgame
(01:13:40) - Postmortem & Playbook
CREDITS
Co-hosted by Alex Kesin and Matthew Pech
Written, edited, and produced by Alex Kesin
Music: “Food” by nerowski
* Special thanks to the team at NFX for the use of their recording studio.
SOURCES
Last updated: January 2026
I. PRIMARY DOCUMENTS
FDA Regulatory Documents
Symlin (pramlintide acetate) - NDA 21-332
* Approval Letter & Package (March 16, 2005)
* Clinical Pharmacology & Biopharmaceutics Review
* Administrative Documents & Correspondence
Byetta (exenatide) - NDA 21-773
* Approval Letter & Package (April 28, 2005)
* Clinical Pharmacology & Biopharmaceutics Review
* Administrative Documents & Correspondence
Bydureon (exenatide ER) - NDA 22-200
* Approval Letter (January 27, 2012)
* Other Action Letters (Complete Response)
* REMS
* Administrative Correspondence
SEC Filings & Financial Documents
* Amylin 2005 Results Press Release (Ex-99.1, 8-K)
* Amylin 2007 Results Press Release (Ex-99.1)
* Amylin 2011 Form 10-K (Net Product Sales)
* Carl Icahn SEC Filing (Schedule 13D)
Proxy Fight & Legal Documents
* Carl Icahn Letter to Amylin (April 15, 2009)
* Amylin Response to Icahn (April 20, 2009)
* Police Fund v. Bradbury (Amylin) Trial (May 4, 2009)
* Lilly Litigation Ruling (May 25, 2011)
II. ORAL HISTORY & INTERVIEWS
* Howard Greene Oral History (UCSD Library, October 8, 2008) - Primary source for Hybritech founding, Ted Greene’s background, and early Amylin history
III. NEWS & TRADE PRESS
2000
* “The Rumsfeld Resume” - CBS News (December 28, 2000) - Donald Rumsfeld’s board tenure at Amylin (1991-1996)
* “Roller Coasting” - Forbes (July 24, 2000) - Joe Cook narrative, J&J partnership collapse
2005
* “Investing for a Profit and a Daughter’s Health” - NYT (March 19, 2005) - Allen Andersson investment story, “tablecloth deal”
2006
* “Diabetics see hope (and weight loss) in new drug” - NYT (March 2, 2006) - “Lizzie” nickname, patient testimonials
* “4 Diabetes Drugs Are Seen Raising Hope and Profit” - NYT (June 22, 2006) - Manufacturing shortage, 400,000+ patients
* “Don’t kill off life-saving drugs” - Heritage Foundation (August 15, 2006) - Policy perspective on Byetta’s potential impact
* “Byetta Craze Is First Salvo in Promising New Line of Drugs” - diaTribe - ADA conference chaos, “one man cried”
2007
* Dr. John Eng Profile - Diabetes In Control (September 18, 2007) - Eng’s discovery story, patent struggles, Amylin vs. Lilly negotiations
2008
* Xenome/Amylin Partnership - BioSpace (February 5, 2008) - Venom peptide library partnership
2009
* Eastbourne Capital Sells Stake - San Diego Union-Tribune (October 10, 2009) - End of Eastbourne activist campaign
Podcasts similares
Más podcasts de Economía y empresa
¿Es tu podcast?
Confírmalo con una entrada en tu feed: aquí recibes un código, lo añades como podcast:txt en el canal de tu feed y nosotros lo comprobamos. Después tu podcast aparecerá como «verificado» en SoundNode.